Supporting HER2+ mBC Patients in Later Lines: AE Management and the Role of the Multidisciplinary Team

Opinion
Video

Experts discuss treatment options for HER2-positive metastatic breast cancer following progression on trastuzumab deruxtecan (T-DXd), weighing real-world data on tucatinib-capecitabine-trastuzumab versus T-DM1, considering factors such as resistance mechanisms, administration preferences, and side effect management.

Video content above is prompted by the following:

  • What real world data following the use of Tucatinib and T-DXd that can help assist medical professionals.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
4 experts in this video
4 experts in this video
Photo of a man wearing glasses and a suit in front of a blue background
Related Content
Graphic of a person with a breast tumor

Awareness of Actionable Mutations Guides mBC Treatment Post-Endocrine

Bridget Hoyt
July 16th 2025
Article

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

graphic of a breast with a tumor

KN026/KN046 Combo Yields Durable Responses in HER2+ mBC

Jax DiEugenio
July 7th 2025
Article

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Graphic of a breast with tumors

Gedatolisib Combos Show Early Activity in mCRPC, Metastatic Breast Cancer

Tim Cortese
July 3rd 2025
Article

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Anatomical graphic of a person with a tumor in their left breast

First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

Russ Conroy
June 4th 2025
Article

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Graphic of a breast with a tumor.

Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

Bridget Hoyt
May 22nd 2025
Article

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.